In recent years, the state has introduced a number of good policies, combined efforts to drive paediatric drug innovation and research and development. 2023 to date, more than 120 paediatric drugs have been approved by the NMPA to market, of which 39 were approved for the first time, focusing on the neurological drugs, antitumor and immunomodulators and other therapeutic categories; 32 through the priority review and approval process to accelerate the listing of the well-known pharmaceutical companies involved in the Hengrui Medicine, Jichuan Pharmaceuticals and so on. In July, a new round of national talks was officially launched, 56 paediatric drugs are expected to rush the line 2024 national talks, solutions and injections in the number of leading; exclusive varieties (including the dosage form of exclusive) for the main force, accounting for more than 60%.
China is the world's second largest paediatric drug market, according to the National Bureau of Statistics data, in 2020, the number of children aged 0-14 years old population of 253 million people, accounting for about 18% of the country's total population. With the full liberalisation of the "three-child" policy, the demand for paediatric drugs is also increasing.